NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor β1 production

Hye Young Kim,1,2 Hyun Jung Kim,1,2 Hye Sook Min,1 Sanghee Kim,4 Weon Seo Park,2 Seong Hoe Park,1,2 and Doo Hyun Chung1,2,3

1Department of Pathology, 2Graduate School of Immunology, 3Rheumatism Research Center, College of Medicine, and 4Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 110-799, Korea

Although NKT cells has been known to exert protective roles in the development of autoimmune diseases, the functional roles of NKT cells in the downstream events of antibody–induced joint inflammation remain unknown. Thus, we explored the functional roles of NKT cells in antibody–induced arthritis using the K/BxN serum transfer model. NKT cell–deficient mice were resistant to the development of arthritis, and wild-type mice administrated with α-galactosyl ceramide, a potent NKT cell activator, aggravated arthritis. In CD1d−/− mice, transforming growth factor (TGF)-β1 was found to be elevated in joint tissues, and the blockade of TGF-β1 using neutralizing monoclonal antibodies restored arthritis. The administration of recombinant TGF-β1 into C57BL/6 mice reduced joint inflammation. Moreover, the adoptive transfer of NKT cells into CD1d−/− mice restored arthritis and reduced TGF-β1 production. In vitro assay demonstrated that interleukin (IL)-4 and interferon (IFN)-γ were involved in suppressing TGF-β1 production in joint cells. The adoptive transfer of NKT cells from IL-4−/− or IFN-γ−/− mice did not reverse arthritis and TGF-β1 production in CD1d−/− mice. In conclusion, NKT cells producing IL-4 and IFN-γ play a role in immune complex–induced joint inflammation by regulating TGF-β1.

NKT cells express intermediate levels of a semi-invariant Vα14-Jα281 (Vα14i) TCR in mice or an invariant Vα24-Jα15 TCR in humans (1), which recognizes glycolipid antigens presented by the CD1d (2). Upon activation, NKT cells rapidly produce large amounts of IL-4 and IFN-γ (3), which have been demonstrated to play critical roles in the regulation of innate and adaptive immune responses by NKT cells (4). Thus, it has been proposed that NKT cells exert regulatory functions in autoimmune diseases by establishing an early cytokine environment. In animal models, NKT cells have been reported to affect the development and progression of diabetes mellitus (5), experimental autoimmune encephalitis (6), and systemic lupus erythematosus (7). However, the functional roles of NKT cells in the development of autoimmune arthritis have not been completely explored.

Recently, a spontaneous murine arthritis model was developed by breeding KRN TCR transgenic (Tg) mice in the background of B6 to the nonobese diabetic (NOD) mice (8). KRN TCR has been reported to be specific for a peptide of bovine RNase (42–56) bound to I-Ak presented by APCs (8). The offspring (K/BxN) spontaneously develop a progressive joint-specific autoimmune disease (8). In K/BxN mice, T cells with KRN TCR recognize peptide derived from glucose-6-phosphate isomerase in the context of I-Ak7 expressed on APCs, and B cells produce arthrogenic Ig against glucose-6-phosphate isomerase (9). The transfer of serum from K/BxN mice into susceptible mice induces a synchronized joint inflammation that mimics K/BxN disease (10). Unlike other arthritis animal models, the K/BxN serum transfer model is confined to the inflammatory responses induced by the deposition of autoantibody in joint spaces (10). Thus, it allows one to explore the downstream events of antibody–induced joint inflammation and the terminal effector mechanism of rheumatoid arthritis (RA). Recently NKT cells were reported to be a subpopulation of T cells that critically exert a functional link between innate and adaptive responses in vivo (1).
Nevertheless, the role of NKT cells at the end-stage of the effector mechanism of joint inflammation where innate immune responses are critically involved remains unclear.

Our results show that NKT cells play an indispensable role in the induction of immune complex–induced joint inflammation by suppressing TGF-β1 production in joint tissues, which in turn is dependent on IL-4 and IFN-γ secreted by NKT cells.

RESULTS AND DISCUSSION
NKT cells promote joint inflammation in the antibody-induced arthritis

To determine the specific role of NKT cells in the development of antibody-induced arthritis, we examined NKT cell–deficient mice, CD1d−/− and Jα281−/− mice, and B6 mice in the K/BxN serum transfer model. Whereas B6 mice showed measurable swelling at 3–4 d after serum transfer, which peaked at 8–9 d, CD1d−/− and Jα281−/− mice were resistant to the development of joint inflammation for 6 d and showed a gradual increase in ankle swelling after 7 d (Fig. 1 A). The maximal thickness of joint swelling in CD1d−/− and Jα281−/− mice was much smaller than that of B6 mice. Histological examination of the ankle joints of B6 mice at 5 d revealed a marked infiltration of neutrophils in synovial fluid and connective tissues (Fig. 1 B). Unlike B6 mice, CD1d−/− and Jα281−/− mice showed mild inflammatory cell infiltration in ankle joints and surrounding connec-

Figure 1. NKT cell–deficient mice attenuate arthritis in the K/BxN serum transfer model. (A) Clinical scores and ankle thickness was monitored in Jα281−/− (black triangle), CD1d−/− (black circle), and B6 mice (black square) after injection of K/BxN serum. (B) Histological examination of the ankle joint of a B6 mouse and of Jα281−/− and CD1d−/− mice 5 d after serum transfer. A magnification of 12.5 in the top panels and 40 in the bottom panels. (C) RT-PCR was used to determine the level of Vα14Jα281 TCR mRNA in the ankle joint tissues of B6 mice and CD1d−/− mice 3, 5, 7, and 14 d after K/BxN serum transfer. (D) Sorted NKT cells (3 × 10⁵ cells/mouse) from B6 mice (white square) were adoptively transferred into CD1d−/− mice 1 d before K/BxN serum transfer. Clinical scores and ankle thickness were monitored and compared with B6 (black square) and CD1d−/− mice (black circle). Data are the means ± SEM of three mice in each group. These results are taken from a representative one of six repeated experiments (A and C).
tive tissues (Fig. 1 B). To test for the infiltration of NKT cells in joint tissues, we measured the level of \(V\alpha_{14}\gamma_2\delta_1\) TCR mRNA in the joint tissue of B6 mice after K/BxN serum transfer. RT-PCR assays showed \(V\alpha_{14}\gamma_2\delta_1\) TCR mRNA at 3, 5, and 7 d after serum injection and weak intensity band on day 14, which was not demonstrated in CD1d\(^{-/-}\) mice (Fig. 1 C). However, no transcripts for \(V\alpha_{14}\gamma_2\delta_1\) TCR were detected in the joint of B6 mice at day 0, indicating that NKT cells infiltrate joint tissues during antibody-induced arthritis (not depicted). To demonstrate day 0, indicating that NKT cells infiltrate joint tissues during arthritis.

Activated joint inflammation during K/BxN serum–transferred NKT cells in the absence of conventional full/jem.20041400/DC1). Splenocytes from V\(\alpha_{14}\) TCR Tg RAG\(^{-/-}\) mice contain a large number of V\(\alpha_{141}\) T cells and B cells compared with those from C57BL/6 mice, whereas the splenocytes of J\(\alpha_{281}\) mice are deficient in V\(\alpha_{141}\) TCR NKT cells (4). These data indicate that adoptively transferred NKT cells restored arthritis in CD1d\(^{-/-}\) mice in the K/BxN serum transfer model. Next, we investigated whether the activation of NKT cells affects arthritis using \(\alpha\)-galactosyl ceramide (\(\alpha\)-GalCer), a potent NKT cell stimulant. When we injected B6 mice with \(\alpha\)-GalCer, joint swelling in these mice was aggravated (Fig. 2). These data indicate that the in vivo activation of NKT cells using \(\alpha\)-GalCer aggravated joint inflammation during K/BxN serum–transferred arthritis.

It has been reported that patients with RA have abnormalities in the number of TCR \(\alpha\)V2\(^{+}\)\(\beta\)V11\(^{+}\) double negative NKT cells in peripheral blood lymphocytes compared with healthy persons (12). In the mouse system, the administration of OCH, a sphingosine-truncated analogue of \(\alpha\)-GalCer, into B6 mice inhibits collagen-induced arthritis (13). These results provide supporting evidence of the protective roles of NKT cells in autoimmune arthritis. However, our results demonstrate that NKT cells provoke inflammatory responses in the joint tissues of the K/BxN serum transfer model. Theses contradictory findings for the functional roles of NKT cells in joint inflammation led us to speculate that NKT cells play diverse roles in autoimmune arthritis depending on the disease processes. In the K/BxN serum transfer model, the immune complexes on the cartilage surface were found to engage FcγRIII on mast cells and macrophages in the synovium (8, 14). These findings indicate that the K/BxN serum transfer model is one of the typical Arthus reactions, which does not include adoptive immune responses. Thus, the provocative roles of NKT cells in the K/BxN serum transfer model represent a novel function in immune complex–induced inflammatory responses and not the suppressive role of NKT cells described in adoptive autoimmune responses (5, 15). However, NKT cells play different roles in different models for antibody-induced autoimmune diseases. A recent report has provided evidence that \(\alpha\)-GalCer suppresses disease in a model for Graves’ thyroiditis (16), whereas the functional roles of NKT cells was not found in an experimental autoimmune myasthenia gravis model (17). Taken together, it is conceivable that NKT cells have a dual functionality that depends on the disease processes of RA, a suppressive role in the inductive phase, and a provocative role with respect to antibody-induced joint inflammation.

**TGF-\(\beta\)1 exerts antiinflammatory effects on antibody–induced arthritis**

To evaluate the mechanism by which NKT cells contribute to the development of arthritis, we measured the mRNA levels of various proinflammatory cytokines in joint tissues. Upon K/BxN serum transfer, CD1d\(^{-/-}\) mice showed higher levels of the TGF-\(\beta\)1 transcript, whereas B6 mice showed reduced levels of the TGF-\(\beta\)1 transcript on days 3, 5, 7, and 14. Conversely, IFN-\(\gamma\) and IL-4 were lower in CD1d\(^{-/-}\) mice than in B6 mice (Fig. 3 A). In contrast to joint tissues, the transcript levels of TGF-\(\beta\)1, IL-4, and IFN-\(\gamma\) in the spleen were similar in B6 and CD1d\(^{-/-}\) mice in the K/BxN serum transfer model (Fig. 3 B). The reconstitution of CD1d\(^{-/-}\) mice with either NKT cells from B6 or \(V\alpha_{14}\gamma_2\delta_1\) TCR Tg RAG\(^{-/-}\) mice reduced TGF-\(\beta\)1 mRNA and increased the levels of IFN-\(\gamma\) and IL-4 transcript in the joint tissues (Fig. 3 B and Fig. S1 B). In contrast, the adoptive transfer of NKT cells did not alter the transcript level of TGF-\(\beta\)1 or IFN-\(\gamma\) and IL-4 in the spleens of CD1d\(^{-/-}\) mice (Fig. 3 B). These results suggest that the TGF-\(\beta\)1 might be involved in the resistance to joint inflammation shown by CD1d\(^{-/-}\) mice, and this is tightly regulated by NKT cells infiltrating joint tissue in the K/BxN serum transfer model. To establish a functional link between TGF-\(\beta\)1 activity and arthritis, a blocking anti–TGF-\(\beta\) mAb and recombinant TGF-\(\beta\)1 were injected i.p into CD1d\(^{-/-}\) and B6 mice in a K/BxN serum transfer model. TGF-\(\beta\)1...
NKT CELLS PROMOTE ANTIBODY-INDUCED ARTHRITIS | Kim et al.

blockade in CD1d<sup>−/−</sup> mice induced a significant increase in joint swelling and clinical index, whereas TGF-β1 blockade in B6 mice did not apparently increase joint inflammation (Fig. 3 C). The recombinant TGF-β1 administered into B6 mice suppressed joint inflammation as compared with B6 mice in the serum transfer model (Fig. 3 D). These findings revealed that the regulatory effects of NKT cells on arthritis depend on the amount of TGF-β1 produced in joint tissues. However, the roles of NKT cells as effector cells were not completely ruled out in antibody-induced joint inflammation. Therefore, its effector functions in this model should be explored further.

In animal models, TGF-β1 down-regulates proinflammatory cytokine production and exerts protective effects on collagen-induced arthritis in mice (18). Conversely, it has been demonstrated that TGF-β is also capable of promoting inflammation by enhancing neutrophil infiltration and the induction of angiogenesis in joint tissues (19). Thus, it has been suggested that the balance between the proinflammatory and antiinflammatory effects of TGF-β1 in joint inflammation is crucial to RA outcome (20).

**TGF-β1 production in synovium is suppressed by IL-4 and IFN-γ secreted by NKT cells**

To explore how NKT cells induce arthritis by regulating the production of TGF-β1 in our model, synovial cells were taken from mice treated with K/BxN serum and then cultured with Con A to induce the production of TGF-β1. TGF-β1 production was suppressed by the activation of NKT cells using α-GalCer and restored by blocking the interaction between CD1d and TCR on NKT cells with anti-CD1d mAb (Fig. 4 A). Furthermore, when we injected B6 mice...
mice with α-GalCer, TGF-β1 production in joint tissues was reduced versus control mice in the K/BxN serum transfer model (Fig. 4 B). These results indicate that activated NKT cells specifically suppress the production of TGF-β1 by immune cells of synovium. It is well known that NKT cells secrete IL-4, IFN-γ, and IL-13 and enhance the production of IL-10 in vivo upon activation (3, 4, 21). Thus, we attempted to identify cytokines involved in the suppression of TGF-β1 production by NKT cells. IL-4, IL-10, IL-13, and IFN-γ were neutralized by specific mAbs during synovial and NKT cell activation in culture. Among the blocking mAbs tested, mAbs against IL-4 and IFN-γ partially restored TGF-β1 production, whereas mAbs against IL-10, IL-13, and control IgG had no effect (Fig. 4 A). These results suggest that IL-4 and IFN-γ secreted by NKT cells might be involved in the suppression of TGF-β1 production by synovial cells. Interestingly, a recent report provided evidence that CD1d-restricted T cells promote TGF-β production through IL-13 using a tumor model (22). However, IL-13 did not seem to be a major regulatory cytokine for production of TGF-β1 in vivo (23, 24). These findings explain how IFN-γ regulates joint inflammation by suppressing TGF-β1 production in vivo. Several experiments demonstrated that IFN-γ is a negative regulator of TGF-β production and of the effects of TGF-β on immune cells in vivo and in vitro (23, 24). These findings explain how IFN-γ regulates joint inflammation by suppressing TGF-β1 production in joint tissue. On the contrary to previous studies reporting that IL-4 promotes the differentiation of TGF-β-producing CD4+ T cells (23), our study shows that IL-4 secreted by NKT cells suppress the production of TGF-β1 in joint tissues. It remains unclear how IL-4 suppresses TGF-β1 production in the joint tissues of the K/BxN serum transfer model. Thus, we speculate that the effects of IL-4-induced cytokine production might be diverse depending on the different maturational stage of the responding cells and/or the murine model system.

Figure 4. The suppressive effects of NKT cells on TGF-β1 production in joint tissues are dependent on IL-4 and IFN-γ secreted from NKT cells. (A) Synovial cells were taken from B6 mice treated with K/BxN serum and cultured with Con A and α-GalCer. IL-4, IL-10, IL-13, and IFN-γ were neutralized, and CD1d was blocked using mAbs during synovial cell activation. TGF-β1 production by synovial cells was determined by ELISA. (B) B6 mice were injected with α-GalCer, and TGF-β1 transcript levels were measured in the ankle joint tissues by real-time PCR. (C) Sorted NKT cells (5 × 10^5 cells/mice) from IL-4−/− mice (white circle), (D) IFN-γ−/− mice (white circle), and B6 (white square) were adoptively transferred into CD1d−/− mice in the K/BxN serum transfer model. Joint swelling was measured and compared with B6 (black square) and CD1d−/− controls (black circle). The level of TGF-β1 mRNA was measured in the ankle joint tissues of B6, CD1d−/−, and CD1d−/− mice treated with either sorted NKT cells from B6 or IL-4−/− or IFN-γ−/− mice by real-time PCR 7 d after serum transfer.

Nevertheless, the mechanism for the suppression of TGF-β1 by IL-4 in this model should be explored further.

In summary, our studies suggest that NKT cells in joint tissue may play an essential role in the end-stage effector phase of RA, and that inflammatory responses in RA might be regulated by modulating NKT cells in joint tissues.

MATERIALS AND METHODS

Mice. KRN TCR Tg mice and NOD mice were provided by D. Mathis and C. Benoist (Harvard Medical School, Boston, MA) and from the Institut
de Génétique et de Biologie Moléculaire et Cellulaire, and were maintained in a C57BL/6(B6) background (K/B). Arthritic mice (K/BxN) were obtained by crossing K/B with NOG (N) mice. CD11c-/- mice were provided by Hua Gu (Columbia University, New York, NY). Jx81,14i/- and RAG-/- were purchased from The Jackson Laboratory. B6 mice were purchased from DaeHan Biolink. These mice were bred and maintained under specific pathogen-free conditions at the Clinical Research Institute Seoul National University Hospital (CRISNUH). All animal experiments was performed after receiving approval of the Institutional Animal Care and Use Committee of CRISNUH.

**Serum transfer and arthritis scoring.** Arthritic adult K/BxN mice were bled and sera were pooled. Recipient mice were injected i.p. with 150 µl (except for the experiment for α-GaCer stimulation in vivo) of pooled K/BxN sera on days 0 and 2. Ankle thickness was measured with a caliper (Manostat). Joint swellings were monitored and scored as follows. 0, no joint swelling; 1, swelling of one finger joint; 2, mild swelling of wrist or ankle; 3, severe swelling of wrist or ankle.

**Histological examination.** Whole knee joints and hind paws were fixed in 10% formalin, deparaffinized, and paraffin embedded. Sections were prepared from the joint tissue blocks and stained with hematoxylin and eosin.

**Adoptive transfer experiment.** After mice were killed, livers were homogenized and resuspended in loading buffer (PBS plus 10% FBS and 1 mM EDTA) and overlaid onto lympholyte-M (Cedarlane). After centrifugation for 20 min at 900 g, liver mononuclear cells were isolated from the interface. Obtained cells were stained with PE-conjugated anti-NK1.1 (BD Biosciences) and CyChrome-conjugated anti-TCR-B (BD Biosciences). Stained cells were then sorted by FACStarPlus using CELLQuest software, and the purity of sorted cells was >98%.

**Real-time PCR and RT-PCR analysis.** The joint tissues were homogenized using a Polytron and TRIzol reagent, and total RNA was isolated. 5 µg RNA was reverse transcribed with Moloney Murine Leukemia virus RT (Koschेथ) and then PCR was performed. The following primers were synthesized by Applied Biosystems: GGTGGATGGCCCCTC-VIC; IFN-γ/H9262 reverse, GACGTCAAAAGACAGCCAC-TAMRA. The real-time PCR primer for IL-4 was purchased from Biosource International. The results for each cytokine are normalized with respect to GAPDH expression. The primers for V14i14j281 TCR, are CTAAGCA-CAGACGCTGCACA forward and AGGTGATGACAATCAGCAGT-GTCC reverse.

**Synthesis of α-GaCer.** α-GaCer was synthesized using the method developed by Kim et al. (25).

**Cytokine neutralization and ELISA.** Synovial fluids were taken from B6 mice, administrated K/BxN serum, and cultured with Con A (Sigma-Aldrich) and α-GalCer. Anti–IL-4, anti–IL-10, and anti–IL-13 mAbs (R&D Systems) and anti–IFN-γ mAb (American Type Culture Collection [ATCC]) were used to neutralize the respective cytokines in the concentration of 30 µg/ml. CD1d was blocked using 5 µg of blocking mAbs (BD Biosciences) during synovial cell activation. TGF-β1 production was measured using ELISA (BD Biosciences). The hybridomas for anti–TGF-β (clone:1D11.16.8), anti–IFN-γ (clone: R4-62A), and IL-4 mAb (clone HB188) were purchased from ATCC. 500 µg of each of mAb was injected i.p. three times per week. 1 µg rhTGF-β1 (R&D Systems) was injected i.p. into B6 mice twice before and after the administration of K/BxN serum.

**Online Supplemental Materials.** Fig. S1 shows that the adoptive transfer of V14i cells restores joint inflammation and suppresses TGF-β1 production in CD11c-/- mice. Fig. S2 shows that the blockade of IL-4 or IFN-γ in V14i14j281 TCR, Tg RAG-/- mice reduces joint inflammation and does not suppress TGF-β1 production in synovium. Figs. S1 and S2 are available at http://www.jem.org/cgi/content/full/jem.20041400/DC1.

We thank Drs. Kyeong Cheon Jung, Wan Uk Kim, Youngmee Bae, and Eun Young Choi for helpful comments on the manuscript, and all members of the Department of Experimental Animal CRISNUH for animal management.

This work was supported by a grant (R11-2002-098-01003-0) from the Korea Science & Engineering Foundation through the RRC, and grant (03-2004-006-0) from the SHNU Research Fund.

The authors have no conflicting financial interests.

Submitted: 12 July 2004
Accepted: 29 November 2004

**REFERENCES**

1. Lantz, O., and A. Bendelac. 1994. An invariant T cell receptor α chain is used by a unique subset of MHC class I-specific CD4+ and CD4–8 T cells in mice and humans. J. Exp. Med. 180:1097–1106.

2. Bendelac, A. 1995. CD1: presenting unusual antigens to unusual T lymphocytes. Science. 269:185–186.

3. Chen, H., and W.E. Paul. 1997. Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-γ upon activation by anti–CD3 or CD1. J. Immunol. 159:2240–2249.

4. Taniguchi, M., M. Harada, S. Kojo, T. Nakayama, and H. Wakao. 2003. The regulatory role of V14i NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21:483–513.

5. Hong, S., M.T. Wilson, I. Serizawa, L. Wu, N. Singh, O.V. Naidenko, T. Miura, T. Haba, D.C. Scherer, J. Wei, et al. 2001. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in NOD mice. Nat. Med. 7:1052–1056.

6. Singh, A.K., M.T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, A.K. Stanic, S. Joyce, S. Siriram, Y. Koezuka, and L. Van Kaer. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194:1801–1811.

7. Yang, J.Q., A.K. Singh, M.T. Wilson, M. Satoh, A.K. Stanic, J. Park, S. Hong, S.D. Gidola, A. Mizutani, S.R. Kakumatu, et al. 2003. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J. Immunol. 171:2142–2153.

8. Kouskoff, V., A.S. Korgaonkar, V. Duchatelie, C.Degott, C. Benoist, and D. Mathis. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell. 87:811–822.

9. Matsumoto, I., A. Staub, C. Benoist, and D. Mathis. 1999. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science. 286:1732–1735.

10. Ji, H., D. Gauguier, K. Ohmura, A. Gonzalez, V. Duchatelie, P. Danoy, H.J. Garchon, C. Degott, M. Lathrop, C. Benoist, and D. Mathis. 2001. Genetic influences on the end-stage effector phase of arthritis. J. Exp. Med. 194:321–330.

11. Campos, R.A., M. Szczepanik, A. Itakura, M. Akahira-Azuma, S. Sido-bre, M. Kronenberg, and P.W. Askenase. 2003. Cutaneous immunity provoked by linked T and B cell recognition of a glycolytic enzyme. J. Exp. Med. 198:1732–1735.

12. Kojo, S., Y. Adachi, H. Keino, M. Taniguchi, and T. Sumida. 2001. Dysfunction of T cell receptor αV2α1β18*, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum. 44:1127–1138.

13. Chuba, A., S. Oki, K. Miyamoto, H. Hashimoto, T. Yamamura, and S. Miyake. 2004. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a spongious-truncated analog of alpha-galactosylceramide. Arthritis Rheum. 50:305–313.

14. Bruns, P., A. Samuelsson, J.W. Pollard, and J.V. Ravetch. 2003. Colony-stimulating factor-1-dependent macrophages are responsible for IFNg protection in antibody-induced autoimmune disease. Immunity.
18:573–581.
15. Zeng, D., Y. Liu, S. Sidobre, M. Kronenberg, and S. Strober. 2003. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J. Clin. Invest. 112:1211–1222.
16. Nagyama, Y., K. Watanabe, M. Niwa, S.M. McLachlan, and B. Rapoport. 2004. Schistosoma mansoni and α-galactosylceramide: prophylactic effect of Th1 immune suppression in a mouse model of Graves’ hyperthyroidism. J. Immunol. 173:2167–2173.
17. Shi, F.D., H.B. Wang, H. Li, S. Hong, M. Taniguchi, H. Link, L. Van Kaer, and H.G. Ljunggren. 2000. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1:245–251.
18. Kuruvilla, A.P., R. Shah, G.M. Hochwald, H.D. Liggitt, M.A. Palladino, and G.J. Thorbecke. 1991. Protective effect of transforming TGF-β1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA. 88:2918–2921.
19. van Beuningen, H.M., P.M. van der Kraan, O.J. Arntz, and W.B. van den Berg. 1994. TGF-β1 stimulates articular chondrocyte proteoglycan synthesis and induces osteocyte formation in the murine knee joint. Lab. Invest. 71:279–290.
20. O’Shea, J.J., A. Ma, and P. Lipsky. 2002. Cytokines and autoimmunity. Nat. Rev. Immunol. 2:37–45.
21. Akbari, O., P. Stock, E. Meyer, M. Kronenberg, S. Sidobre, T. Nakayama, M. Taniguchi, M.J. Grubr, R.H. DeKruyff, and D.T. Umetsu. 2003. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9:582–588.
22. Terabe, M., S. Matsui, J.M. Park, M. Mamura, N. Noben-Trauth, D.D. Donaldson, W. Chen, S.M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. TGF-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198:1741–1752.
23. Marth, T., W. Strober, R.A. Seder, and B.L. Kelsall. 1997. Regulation of TGF-β production by interleukin-12. Eur. J. Immunol. 27:1213–1220.
24. Seder, R.A., T. Marth, M.C. Sieve, W. Strober, J.J. Letterio, A.B. Roberts, and B. Kelsall. 1998. Factors involved in the differentiation of TGF-β-producing cells from naïve CD4+ T cells: IL-4 and IFN-γ have opposing effects, while TGF-β positively regulates its own production. J. Immunol. 160:5719–5728.
25. Kim S., T. Lee, S. Jung, and D. Kim. 2004. Practical synthesis of KRN7000 form phytosphingosine. Synthesis 22:847–850.